INFRAFRONTIER Achieves ERIC Status: Advancing Biomedical Research in Europe
INFRAFRONTIER, a leading player in biomedical research infrastructure, headquartered at Helmholtz Munich, was officially declared as a European Research Infrastructure Consortium (ERIC) by the European Commission. This milestone represents a significant leap forward for the pan-European Consortium in its mission to advance scientific cooperation and innovation on a broader European scale.
INFRAFRONTIER is dedicated to modelling human diseases. Operated by a network of over 20 leading biomedical research institutes, it facilitates access to cutting-edge services resources and data for researchers studying gene function in health and disease. The main aims are to advance biomedical research and translation by improving the understanding of human diseases, such as cancer and rare genetic disorders.
On December 20th, the European Commission officially declared INFRAFRONTIER’s transformation into a European Research Infrastructure Consortium. The ERIC is a specialized legal entity designed to streamline the establishment and management of Research Infrastructures (RI) of European significance. By organizing and consolidating research endeavors and resources across the European Research Area, ERIC enables substantial collective investments in research and innovation throughout Europe.
New Era of Collaboration
The new ERIC status marks a pivotal moment in the evolution of INFRAFRONTIER and allows the Consortium to operate as a legal entity under European law. With its headquarter situated at Helmholtz Munich and Founding Members from the Czech Republic, Finland, France, Greece, and Sweden, INFRAFRONTIER ERIC will coordinate the operation of the distributed INFRAFRONTIER Research Infrastructure on a broader European scale.
“We are delighted by the European Commission’s official declaration of INFRAFRONTIER’s transformation into an ERIC,”, says Prof. Martin Hrabě de Angelis, Founding Director of INFRAFRONTIER ERIC, Research Director and Director of the Institute of Experimental Genetics at Helmholtz Munich. “This achievement underscores our unwavering commitment to advancing scientific cooperation and driving innovation within Europe and on a global level. As an ERIC, we are poised to usher in a new era of collaboration and discovery in biomedical research.”
The establishment of INFRAFRONTIER ERIC heralds exciting times ahead for the European research community. With its expanded mandate and enhanced capabilities, INFRAFRONTIER is primed to catalyze breakthroughs that will shape the future of human health and disease understanding.
About the scientist
Prof. Martin Hrabě de Angelis, Founding Director of INFRAFRONTIER ERIC, Research Director at Helmholtz Munich, Director of the Institute of Experimental Genetics Helmholtz Munich and Full Professor and Chair of Experimental Genetics Technical University Munich Germany
